These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 14584080)

  • 61. Quantitative correlation between promoter methylation and messenger RNA levels of the reduced folate carrier.
    Yang R; Li WW; Hoang BH; Kim H; Banerjee D; Kheradpour A; Healey JH; Meyers PA; Bertino JR; Gorlick R
    BMC Cancer; 2008 May; 8():124. PubMed ID: 18452618
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Functional analysis of altered reduced folate carrier sequence changes identified in osteosarcomas.
    Flintoff WF; Sadlish H; Gorlick R; Yang R; Williams FM
    Biochim Biophys Acta; 2004 Oct; 1690(2):110-7. PubMed ID: 15469899
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Current aspects of the pathology of osteosarcoma.
    Grundmann E; Roessner A; Ueda Y; Schneider-Stock R; Radig K
    Anticancer Res; 1995; 15(3):1023-32. PubMed ID: 7645921
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Relation between cellular doxorubicin binding ability to nuclear DNA and histologic response to preoperative chemotherapy in patients with osteosarcoma.
    Kusuzaki K; Takeshita H; Murata H; Hirata M; Hashiguchi S; Ashihara T; Hirasawa Y
    Cancer; 1998 Jun; 82(12):2343-9. PubMed ID: 9635526
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Peroxiredoxin 2 as a chemotherapy responsiveness biomarker candidate in osteosarcoma revealed by proteomics.
    Kikuta K; Tochigi N; Saito S; Shimoda T; Morioka H; Toyama Y; Hosono A; Suehara Y; Beppu Y; Kawai A; Hirohashi S; Kondo T
    Proteomics Clin Appl; 2010 May; 4(5):560-7. PubMed ID: 21137073
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The expression significance of serum MiR-21 in patients with osteosarcoma and its relationship with chemosensitivity.
    Hua Y; Jin Z; Zhou F; Zhang YQ; Zhuang Y
    Eur Rev Med Pharmacol Sci; 2017 Jul; 21(13):2989-2994. PubMed ID: 28742209
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Flow cytometry for testing chemosensitivity of malignant bone tumors].
    Zeng J; Hu Y; Pei F; Lei S; Mao Y; Wei Y
    Zhonghua Wai Ke Za Zhi; 1999 Dec; 37(12):737-9. PubMed ID: 11829940
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Overexpression of resistance-related proteins (metallothioneins, glutathione-S-transferase pi, heat shock protein 27, and lung resistance-related protein) in osteosarcoma. Relationship with poor prognosis.
    Uozaki H; Horiuchi H; Ishida T; Iijima T; Imamura T; Machinami R
    Cancer; 1997 Jun; 79(12):2336-44. PubMed ID: 9191521
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Limited penetration of methotrexate into human osteosarcoma spheroids as a proposed model for solid tumor resistance to adjuvant chemotherapy.
    West GW; Weichselbaum R; Little JB
    Cancer Res; 1980 Oct; 40(10):3665-8. PubMed ID: 7438049
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Peri-osteosarcoma adipose computed tomography attenuation and volume for predicting chemotherapy response in pediatric patients.
    Fu D
    Clin Transl Oncol; 2023 Jun; 25(6):1710-1718. PubMed ID: 36640208
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The expression of bone morphogenetic proteins in osteosarcoma and its relevance as a prognostic parameter.
    Sulzbacher I; Birner P; Trieb K; Pichlbauer E; Lang S
    J Clin Pathol; 2002 May; 55(5):381-5. PubMed ID: 11986346
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Polymorphisms and methylation of the reduced folate carrier in osteosarcoma.
    Yang R; Qin J; Hoang BH; Healey JH; Gorlick R
    Clin Orthop Relat Res; 2008 Sep; 466(9):2046-51. PubMed ID: 18528741
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Evaluation of P-glycoprotein (Pgp) expression in human osteosarcoma by high-throughput tissue microarray.
    Gao Y; Liao Y; Shen JK; Feng Y; Choy E; Cote G; Harmon D; Mankin HJ; Hornicek FJ; Duan Z
    J Orthop Res; 2016 Sep; 34(9):1606-12. PubMed ID: 26790551
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Intravitreal methotrexate resistance in a patient with primary intraocular lymphoma.
    Sen HN; Chan CC; Byrnes G; Fariss RN; Nussenblatt RB; Buggage RR
    Ocul Immunol Inflamm; 2008; 16(1):29-33. PubMed ID: 18379939
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Intratumoral differences in methotrexate levels within human osteosarcoma xenografts studied by microdialysis.
    Ekstrøm PO; Giercksky KE; Andersen A; Bruland OS; Slørdal L
    Life Sci; 1997; 61(19):PL275-80. PubMed ID: 9364204
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Quotient imaging with N-13 L-glutamate in osteogenic sarcoma: correlation with tumor viability.
    Reiman RE; Huvos AG; Benua RS; Rosen G; Gelbard AS; Laughlin JS
    Cancer; 1981 Nov; 48(9):1976-81. PubMed ID: 6117369
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Chemoresistance-Related Stem Cell Signaling in Osteosarcoma and Its Plausible Contribution to Poor Therapeutic Response: A Discussion That Still Matters.
    Martins-Neves SR; Sampaio-Ribeiro G; Gomes CMF
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232719
    [TBL] [Abstract][Full Text] [Related]  

  • 78. NKD2 a novel marker to study the progression of osteosarcoma development.
    Sun XZ; Liao Y; Zhou CM
    Eur Rev Med Pharmacol Sci; 2016 Jul; 20(13):2799-804. PubMed ID: 27424978
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Impairment of methotrexate transport is common in osteosarcoma tumor samples.
    Sowers R; Wenzel BD; Richardson C; Meyers PA; Healey JH; Levy AS; Gorlick R
    Sarcoma; 2011; 2011():834170. PubMed ID: 21234348
    [TBL] [Abstract][Full Text] [Related]  

  • 80. P-glycoprotein and multidrug resistance.
    Johnston JM
    N Engl J Med; 1996 May; 334(20):1336; author reply 1336-7. PubMed ID: 8609961
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.